Fatal Human Rabies Infection With Suspected Host-Mediated Failure of Post-Exposure Prophylaxis Following a Recognized Zoonotic Exposure-Minnesota, 2021.

Autor:	Holzbauer SM; Minnesota Department of Health, St. Paul, Minnesota, USA.; Career Epidemiology Field Officer Program, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Schrodt CA; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Prabhu RM; Essentia Health, Duluth, Minnesota, USA., Asch-Kendrick RJ; Midwest Medical Examiner's Office, Ramsey, Minnesota, USA., Ireland M; Minnesota Department of Health, St. Paul, Minnesota, USA., Klumb C; Minnesota Department of Health, St. Paul, Minnesota, USA., Firestone MJ; Minnesota Department of Health, St. Paul, Minnesota, USA.; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Liu G; Minnesota Department of Health, St. Paul, Minnesota, USA., Harry K; Minnesota Department of Health, St. Paul, Minnesota, USA., Ritter JM; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Levine MZ; Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Orciari LA; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Wilkins K; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Yager P; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Gigante CM; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Ellison JA; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Zhao H; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Niezgoda M; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Li Y; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Levis R; US Food and Drug Administration, Silver Spring, Maryland, USA., Scott D; US Food and Drug Administration, Silver Spring, Maryland, USA., Satheshkumar PS; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Petersen BW; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Rao AK; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Bell WR; University of Minnesota, Minneapolis, Minnesota, USA., Bjerk SM; Essentia Health, Duluth, Minnesota, USA., Forrest S; Essentia Health, Duluth, Minnesota, USA., Gao W; Allina Health, Minneapolis, Minnesota, USA., Dasheiff R; Essentia Health, Duluth, Minnesota, USA., Russell K; Essentia Health, Duluth, Minnesota, USA., Pappas M; Essentia Health, Duluth, Minnesota, USA., Kiefer J; Essentia Health, Duluth, Minnesota, USA., Bickler W; Essentia Health, Duluth, Minnesota, USA., Wiseman A; Essentia Health, Duluth, Minnesota, USA., Jurantee J; Essentia Health, Duluth, Minnesota, USA., Reichard RR; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Smith KE; Minnesota Department of Health, St. Paul, Minnesota, USA., Lynfield R; Minnesota Department of Health, St. Paul, Minnesota, USA., Scheftel J; Minnesota Department of Health, St. Paul, Minnesota, USA., Wallace RM; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Bonwitt J; Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 Oct 13; Vol. 77 (8), pp. 1201-1208.
DOI:	10.1093/cid/ciad098
Abstrakt:	Background: No human rabies post-exposure prophylaxis (PEP) failure has been documented in the United States using modern cell culture-based vaccines. In January 2021, an 84-year-old male died from rabies 6 months after being bitten by a rabid bat despite receiving timely rabies PEP. We investigated the cause of breakthrough infection. Methods: We reviewed medical records, laboratory results, and autopsy findings and performed whole-genome sequencing (WGS) to compare patient and bat virus sequences. Storage, administration, and integrity of PEP biologics administered to the patient were assessed; samples from leftover rabies immunoglobulin were evaluated for potency. We conducted risk assessments for persons potentially exposed to the bat and for close patient contacts. Results: Rabies virus antibodies present in serum and cerebrospinal fluid were nonneutralizing. Antemortem blood testing revealed that the patient had unrecognized monoclonal gammopathy of unknown significance. Autopsy findings showed rabies meningoencephalitis and metastatic prostatic adenocarcinoma. Rabies virus sequences from the patient and the offending bat were identical by WGS. No deviations were identified in potency, quality control, administration, or storage of administered PEP. Of 332 persons assessed for potential rabies exposure to the case patient, 3 (0.9%) warranted PEP. Conclusions: This is the first reported failure of rabies PEP in the Western Hemisphere using a cell culture-based vaccine. Host-mediated primary vaccine failure attributed to previously unrecognized impaired immunity is the most likely explanation for this breakthrough infection. Clinicians should consider measuring rabies neutralizing antibody titers after completion of PEP if there is any suspicion for immunocompromise. Competing Interests: Potential conflicts of interest. R. M. W. reports a role as a board member for the International Rabies Taskforce. R. L. reports roles on the ID Week Program Committee, the Council of State and Territorial Epidemiologists Executive Board, and the National Foundation for Infectious Diseases Executive Board and serving as an associate editor for AAP Red Book (Report of the Committee on Infectious Diseases) and declares support for attending meetings and/or travel from each; payment or honoraria received for their associate editor role was donated to the Minnesota Department of Health. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu